Røyking og Alzheimers sykdom – en kort oversikt
DOI:
https://doi.org/10.5324/nje.v5i2.262Sammendrag
SAMMENDRAG
En rekke epidemiologiske studier har påvist en invers sammenheng mellom røyking og Alzheimers
sykdom (AD). Den inverse assosiasjonen er sterkere jo høyere forbruk av sigaretter og jo lenger
varighet av røyking. Hos AD pasienter ser man dessuten at røykere har et senere debut-tidspunkt for
sykdommen enn ikke-røykere. En mulig biologisk forklaring er at nikotin kompenserer for tap av
nikotinreseptorer i hjernen, som er et vanlig funn ved AD, og opprettholder derved den kognitive
funksjonen i større grad enn hos ikke-røykere. Alternative forklaringer er konfounding med gener
eller ukjente faktorer. Selektiv død av røykerelaterte sykdommer kan medføre at gjenlevende
røykere har en lavere genetisk disposisjon for AD enn gjenlevende ikke-røykere.
Bjertness E.
Smoking and Alzheimer’s disease - a brief overview.
Nor J Epidemiol
ENGLISH SUMMARY
Several case-control studies have demonstrated an inverse association between smoking and
Alzheimer’s disease (AD). It has been speculated if nicotine from cigarettes compensates for loss of
nicotine receptors, which is a common finding in the brain in AD. Low-dose subcutaneous administration
of nicotine has been shown to improve cognitive function in AD. However, there are reports
indicating that the inverse association is due to confounding with genes or unknown risk factors.
Apolipoprotein E4 is associated both with AD and death from coronary heart disease. Smoking is
also associated with death from coronary heart disease. Therefore cases with ApoE4-associated AD
will be removed from the pool of smokers due to selective death from coronary heart disease,
leading to a higher prevalence of cases with the ApoE4 genotype in the pool of non-smokers.
1995; 5 (2): 151-153.Downloads
Nedlastinger
Publisert
Hvordan referere
Utgave
Seksjon
Lisens
Norsk Epidemiologi licenses all content of the journal under a Creative Commons Attribution (CC-BY) licence. This means, among other things, that anyone is free to copy and distribute the content, as long as they give proper credit to the author(s) and the journal. For further information, see Creative Commons website for human readable or lawyer readable versions.
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
